Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Arthritis and Rheumatism
|
January 11, 2012
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study
Brad H Rovin, Richard Furie, Kevin Latinis, et al.
Kidney International
|
December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy
Sean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
Clinical Pharmacology in Drug Development
|
June 17, 2016
A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy
Wenhui Zhang, Robert M Kernstock, Erik E Karrer, et al.
Annals of the Rheumatic Diseases
|
October 7, 2021
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Richard A Furie, Gustavo Aroca, Matthew D Cascino, et al.
Lupus Science & Medicine
|
June 17, 2026
Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus
Elsa Martins, Vishala L Chindalore, X Rebecca Sheng, et al.
Rheumatology and Therapy
|
August 15, 2019
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
Mark C Genovese, Maria W Greenwald, Sergio R Gutierrez-Ureña, et al.
The New England Journal of Medicine
|
June 5, 2026
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
Fernando C Fervenza, Fan Fan Hou, Chuan-Ming Hao, et al.
Clinical Pharmacology in Drug Development
|
July 14, 2016
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients
Tong Zhu, James Keirns, Corrie Howieson, et al.
The New England Journal of Medicine
|
February 10, 2025
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Richard A Furie, Brad H Rovin, Jay P Garg, et al.
The New England Journal of Medicine
|
March 6, 2026
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus
Richard A Furie, Maria Dall'Era, Edward M Vital, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Arthritis and Rheumatism
|
January 11, 2012
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study
Brad H Rovin, Richard Furie, Kevin Latinis, et al.
Kidney International
|
December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy
Sean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
Clinical Pharmacology in Drug Development
|
June 17, 2016
A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy
Wenhui Zhang, Robert M Kernstock, Erik E Karrer, et al.
Annals of the Rheumatic Diseases
|
October 7, 2021
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Richard A Furie, Gustavo Aroca, Matthew D Cascino, et al.
Lupus Science & Medicine
|
June 17, 2026
Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus
Elsa Martins, Vishala L Chindalore, X Rebecca Sheng, et al.
Rheumatology and Therapy
|
August 15, 2019
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
Mark C Genovese, Maria W Greenwald, Sergio R Gutierrez-Ureña, et al.
The New England Journal of Medicine
|
June 5, 2026
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
Fernando C Fervenza, Fan Fan Hou, Chuan-Ming Hao, et al.
Clinical Pharmacology in Drug Development
|
July 14, 2016
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients
Tong Zhu, James Keirns, Corrie Howieson, et al.
The New England Journal of Medicine
|
February 10, 2025
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Richard A Furie, Brad H Rovin, Jay P Garg, et al.
The New England Journal of Medicine
|
March 6, 2026
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus
Richard A Furie, Maria Dall'Era, Edward M Vital, et al.
Page
of 2